Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2035836 | 0.80 | KMT2A (0.34) | ACEKMT2AADRA2CP2RX7 | |
| SCHEMBL10308857 | 0.78 | ACE (0.34) | ACEPIK3CD | |
| Hydrochloric Acid SCHEMBL29221238 | 0.74 | OPRM1 (0.32) | ACE | |
| SCHEMBL12667198 | 0.73 | — | — | |
| SCHEMBL16181406 | 0.72 | MTOR (0.36) | KMT2AADRA2CPIK3CD | |
| SCHEMBL24398720 | 0.71 | ACE (0.38) | ACEKMT2AADRA2C | |
| SCHEMBL10308957 | 0.71 | MTOR (0.36) | — | |
| SCHEMBL10308951 | 0.70 | MTOR (0.38) | KMT2A | |
| SCHEMBL16181408 | 0.70 | MTOR (0.38) | — | |
| SCHEMBL7600246 | 0.70 | PIK3CD (0.36) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-8933083-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8546429-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8410119-B2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130023527-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8293751-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110112060-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110082134-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7838525-B2 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20070155763-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the phophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICLAS, INC. (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | ARENA PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
| CN-1210264-C | 1,3-dialkyl-2-imidazolinones and its prepn. | MITSUI CHEMICALS INC (JP) | 2005-07-13 | — | — | CN | disclosed |
| EP-0992497-B1 | Manufactoring process for 1,3-Dialkyl-2-imidazolinones | MITSUI CHEMICALS INC (JP) | 2003-12-17 | — | — | EP | disclosed |
| US-6492528-B1 | 1,3-DIALKYL-2-IMIDAZOLIDINONES IN A DIRECT ONE-STEP REACTION FROM INDUSTRIALLY AVAILABLE ALKYLENE CARBONATE, N-ALKYLETHANOLAMINE OR 1,2-DIOL, WHICH CAN MINIMIZE FORMING SOLID MATERIALS AND BE READILY CONDUCTED IN AN INDUSTRIAL | MITSUI CHEMICALS, INC. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1148052-A2 | 1,3-dialkyl-2-imidazolidinones and a manufacturing process therefor | Mitsui Chemicals, Inc. (JP) | 2001-10-24 | — | — | EP | disclosed |
| EP-1148051-A2 | 1,3-dialkyl-2-imidazolidinones and a manufacturing process therefor | Mitsui Chemicals, Inc. (JP) | 2001-10-24 | — | — | EP | disclosed |
| EP-0992497-A1 | 1,3-Dialkyl-2-imidazolidinones and a manufacturing process therefor | Mitsui Chemicals, Inc. (JP) | 2000-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023527-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | CYP7A1, GPR119, UGT1A1 | ACE 692/4885KMT2A 1969/4885ADRA2C 635/4885 |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | PRSS1, PRSS2, ACE2 | ACE 4/4885KMT2A 3149/4885ADRA2C 3233/4885 |
| US-20110112060-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | CYP7A1, CYP27A1, SULT2A1 | ACE 774/4885KMT2A 1951/4885ADRA2C 615/4885 |
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | ACE 503/4885KMT2A 1483/4885ADRA2C 912/4885 |
| US-20110082134-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | CYP7A1, GPR119, UGT1A1 | ACE 692/4885KMT2A 1969/4885ADRA2C 635/4885 |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | GPR119, PC, PLPBP | ACE 828/4885KMT2A 2132/4885ADRA2C 630/4885 |
| US-20070155763-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the phophylaxis and treatment of disorders related thereto | CYP27A1, CYP11B2, CYP11B1 | ACE 1133/4885KMT2A 1987/4885ADRA2C 659/4885 |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | ACE 503/4885KMT2A 1483/4885ADRA2C 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.